For example, preclinical and clinical research together showed that the combination of targeted therapies, like BRAF and MEK inhibition in melanoma and lung cancer, EGFR and MET inhibition in lung cancers, or BRAF and EGFR inhibition in colorectal cancer could lead to prolonged benefits in selected patient groups. Here, BRAF is linked to melanoma.